keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase inhibitor

keyword
https://www.readbyqxmd.com/read/29455298/patient-reported-predictors-of-early-treatment-discontinuation-treatment-related-symptoms-and-health-related-quality-of-life-among-postmenopausal-women-with-primary-breast-cancer-randomized-to-anastrozole-or-exemestane-on-ncic-clinical-trials-group-cctg-ma
#1
Lynne I Wagner, Fengmin Zhao, Paul E Goss, Judith-Anne W Chapman, Lois E Shepherd, Timothy J Whelan, Bassam I Mattar, Jose A Bufill, William C Schultz, Irving E LaFrancis, Gauri G Nagargoje, Radhakrishna Vemuri, Daniel A Nikcevich, George W Sledge, David Cella
PURPOSE: Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane. METHODS: MA...
February 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29453314/ar-expression-in-breast-cancer-ctcs-associates-with-bone-metastases
#2
Nicola Aceto, Aditya Bardia, Ben S Wittner, Maria C Donaldson, Ryan O'Keefe, Amanda Engstrom, Francesca Bersani, Yu Zheng, Valentine Comaills, Kira Niederhoffer, Huili Zhu, Olivia MacKenzie, Toshi Shioda, Dennis Sgroi, Ravi Kapur, David T Ting, Beverly Moy, Sridhar Ramaswamy, Mehmet Toner, Daniel A Haber, Shyamala Maheswaran
Molecular drivers underlying bone metastases in human cancer are not well understood, in part due to constraints in bone tissue sampling. Here, RNA sequencing (RNA-seq) was performed of circulating tumor cells (CTCs) isolated from blood samples of women with metastatic estrogen receptor (ER)+ breast cancer, comparing cases with progression in bone versus visceral organs. Among the activated cellular pathways in CTCs from bone-predominant breast cancer is androgen receptor (AR) signaling. AR gene expression is evident, as is its constitutively active splice variant AR-v7...
February 16, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29452074/differential-control-of-appetitive-and-consummatory-sexual-behavior-by-neuroestrogens-in-male-quail
#3
REVIEW
Charlotte A Cornil, Gregory F Ball, Jacques Balthazart
Estrogens exert pleiotropic effects on multiple physiological and behavioral traits including sexual behavior. These effects are classically mediated via binding to nuclear receptors and subsequent regulation of target gene transcription. Estrogens also affect neuronal activity and cell-signaling pathways via faster, membrane-initiated events. Although the distinction between appetitive and consummatory aspects of sexual behavior has been criticized, this distinction remains valuable in that it facilitates the causal analysis of certain behavioral systems...
February 13, 2018: Hormones and Behavior
https://www.readbyqxmd.com/read/29442401/single-arm-phase-ii-study-of-oral-vitamin-b12-for-the-treatment-of-musculoskeletal-symptoms-associated-with-aromatase-inhibitors-in-women-with-early-stage-breast-cancer
#4
Aleli Campbell, Rosalinda Heydarian, Cecilia Ochoa, Alok Kumar Dwivedi, Zeina A Nahleh
Breast cancer patients receiving endocrine therapy with aromatase Inhibitors (AIs) often experience musculoskeletal and joint-related side effects. The purpose of this study was to evaluate the effect of Vitamin B12 supplements on musculoskeletal symptoms such as pain and arthralgias induced by AIs and to correlate response with serum and inflammatory biomarkers. Upon receiving approval by the Institutional Review Board (IRB), the majority of the patients consented into the study were treated at the Texas Tech Breast Care Center...
February 14, 2018: Breast Journal
https://www.readbyqxmd.com/read/29442014/improvement-of-treatment-outcomes-after-implementation-of-comprehensive-pharmaceutical-care-in-breast-cancer-patients-receiving-everolimus-and-exemestane
#5
M Todo, S Ueda, S Osaki, I Sugitani, T Takahashi, M Takahashi, H Makabe, T Saeki, Y Itoh
Combination therapy with everolimus and an aromatase inhibitor such as exemestane is an effective treatment option for advanced or recurrent breast cancer. However, the therapy is often limited because of the occurrence of severe adverse events (AEs), including oral mucositis, interstitial lung disease, diarrhea, and rash. Therefore, early management of AEs is extremely important to obtain maximum treatment outcome. We investigated here the effects of comprehensive pharmaceutical care for prevention of severe AEs on patient's quality-of-life (QOL) and continuation of therapy...
February 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29441507/economic-evaluation-of-fulvestrant-500-mg-compared-to-generic-aromatase-inhibitors-in-patients-with-advanced-breast-cancer-in-sweden
#6
Ugne Sabale, Mattias Ekman, Daniel Thunström, Claire Telford, Christopher Livings
OBJECTIVES: In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The aim of this study is to assess the cost effectiveness of fulvestrant 500 mg as a second-line hormonal therapy for postmenopausal women with estrogen receptor-positive metastatic or locally advanced BC versus letrozole, anastrozole, and exemestane in Sweden. METHODS: A three-state (pre-progression, post-progression, and death) partitioned-survival model was used to estimate progression-free (PFS) and overall survival (OS) by extrapolating trial results beyond the trial period to capture costs and benefits over a lifetime perspective...
December 2017: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29440043/acupuncture-versus-medication-for-pain-management-a-cross-sectional-study-of-breast-cancer-survivors
#7
Ting Bao, Susan Q Li, Josh L Dearing, Lauren A Piulson, Christina M Seluzicki, Robert Sidlow, Jun J Mao
AIM OF THE STUDY: Breast cancer survivors who take aromatase inhibitors (AI) often suffer from chronic pain. Emerging evidence supports the use of acupuncture as an effective pain management strategy for this condition, but its acceptability among cancer survivors is unknown. We evaluated breast cancer survivors' preferences for acupuncture as compared with medication use and identified factors predictive of this preference. METHODS: We conducted a cross-sectional study among breast cancer survivors who were currently, or had been, taking an AI...
February 10, 2018: Acupuncture in Medicine: Journal of the British Medical Acupuncture Society
https://www.readbyqxmd.com/read/29437768/fda-approval-ribociclib-for-the-treatment-of-postmenopausal-women-with-hormone-receptor-positive-her2-negative-advanced-or-metastatic-breast-cancer
#8
Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Qi Liu, Jingyu Yu, Ping Zhao, Todd R Palmby, Kirsten B Goldberg, C J George Chang, Paresma Patel, Elleni Alebachew, Amy Tilley, William F Pierce, Amna Ibrahim, Gideon M Blumenthal, Rajeshwari Sridhara, Julia A Beaver, Richard Pazdur
On March 13, 2017, the U.S. Food and Drug Administration approved ribociclib (KISQALI, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. The approval was based on a randomized, double-blind, placebo-controlled, international clinical trial (MONALEESA-2)...
February 7, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29431849/medical-treatment-in-the-management-of-deep-endometriosis-infiltrating-the-proximal-rectum-and-sigmoid-colon-a-comprehensive-literature-review
#9
Paolo Vercellini, Laura Buggio, Alessandra Borghi, Ermelinda Monti, Umberto Gattei, Maria Pina Frattaruolo
A comprehensive literature review was performed to evaluate the effect of various hormonal therapies, in terms of variations of intestinal and pain complaints and of patient satisfaction with treatment, in women with symptomatic, non-severely sub-occlusive endometriosis infiltrating the proximal rectum and sigmoid colon. A MEDLINE search through PubMed from 2000 to 2018 was conducted to identify all original English language articles published on medical treatment for colorectal endometriosis. Additional reports were identified by systematically reviewing reference lists and using the "similar articles" function in PubMed...
February 12, 2018: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/29423705/chemotherapeutic-agents-and-the-risk-of-ischemia-and-arterial-thrombosis
#10
REVIEW
Saamir A Hassan, Nicolas Palaskas, Peter Kim, Cezar Iliescu, Juan Lopez-Mattei, Elie Mouhayar, Rohit Mougdil, Kara Thompson, Jose Banchs, Syed Wamique Yusuf
PURPOSE OF REVIEW: Numerous chemotherapeutic agents have been associated with the development of ischemia and arterial thrombosis. As newer therapies have been developed to treat cancer, some of these chemotherapy drugs have been implicated in the development of vascular disease. In this review, we will summarize the most common chemotherapeutic drug classes that may play a role in the development of ischemic heart disease. RECENT FINDINGS: Angiogenesis inhibitors, alkylating agents, antimetabolites, antimicrotubules, and proteasome inhibitors have a number of cardiovascular toxicities...
February 8, 2018: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29409388/are-previous-episodes-of-bacterial-vaginosis-a-predictor-for-vaginal-symptoms-in-breast-cancer-patients-treated-with-aromatase-inhibitors
#11
Malene R Gade, Irina Goukasian, Nathalie Panduro, Claus Kamby, Lisbeth Nilas, Malgorzata K Tuxen, Lars Bjerrum
Objective To estimate the prevalence of vaginal symptoms in postmenopausal women with breast cancer exposed to aromatase inhibitors, and to investigate if the risk of vaginal symptoms is associated with previous episodes of bacterial vaginosis. Methods Patients from Rigshospitalet and Herlev University Hospital, Denmark, were identified through the register of Danish Breast Cancer Cooperation Group and 78 patients participated in the study. Semiquantitave questionnaires and telephone interview were used to assess the prevalence of vaginal symptoms and previous episode(s) of bacterial vaginosis...
January 1, 2018: Post Reproductive Health
https://www.readbyqxmd.com/read/29399271/extended-adjuvant-aromatase-inhibitor-therapy-in-post-menopausal-women
#12
Stephen M Schleicher, Maura N Dickler
Purpose of the review: To understand the evidence for extending adjuvant aromatase inhibitor (AI) therapy from 5 to 10 years in post-menopausal women with hormone receptor positive (HR+) breast cancer. Recent findings: Multiple large trials have investigated this question. The two trials most representative of the dilemma faced in clinical practice are the MA.17R and NSABP-B42 trials, which both investigated the benefit of continuing versus stopping AI therapy beyond 5 years...
December 2017: Current Breast Cancer Reports
https://www.readbyqxmd.com/read/29396856/the-relationship-between-the-cyp2d6-polymorphisms-and-tamoxifen-efficacy-in-adjuvant-endocrine-therapy-of-breast-cancer-patients-in-chinese-han-population
#13
Bo Lan, Fei Ma, Xiaoyu Zhai, Qiao Li, Shanshan Chen, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu
Variants of the CYP2D6 gene may lead to a poor prognosis of tamoxifen (TAM)-treated patients. This study validated the association between the CYP2D6 genotype and outcomes of patients receiving TAM in adjuvant endocrine therapy. A total of 778 breast cancer patients who received adjuvant TAM (n=325) or aromatase inhibitors (AIs) (n=453) at the National Cancer Center were analyzed. Nine single nucleotide polymorphisms (SNPs) in the CYP2D6 gene were selected from online databases. The associations of each SNP genotype with disease-free survival (DFS) and clinicopathological characteristics were analyzed...
February 3, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29396760/interventions-to-improve-endocrine-therapy-adherence-in-breast-cancer-survivors-what-is-the-evidence
#14
REVIEW
Ekim Ekinci, Salima Nathoo, Thushara Korattyil, Aisha Vadhariya, Hanna A Zaghloul, Polly A Niravath, Susan M Abughosh, Meghana V Trivedi
PURPOSE: Endocrine therapy reduces the risk of breast cancer recurrences and mortality in hormone receptor-positive (HR+) breast cancer survivors. However, non-adherence to treatment remains a significant problem. The aim of this study was to review current literature and ongoing trials to identify interventions employed to improve adherence to adjuvant endocrine therapy (AET) in breast cancer survivors. METHODS: We searched PubMed and the National Library of Medicine registry of clinical trials using the terms "breast cancer" and "adherence" or "compliance" and "intervention" and "medication" or "endocrine therapy" or "hormone therapy" to identify published studies as well as ongoing clinical trials...
February 2, 2018: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/29394611/-a-case-of-cecal-cancer-with-para-aortic-lymph-node-metastasis-and-peritoneum-dissemination-treated-with-curative-resection-after-mfolfox6-plus-panitumumab-chemotherapy
#15
Kei Kimura, Masafumi Noda, Ayako Imada, Jihyung Song, Akihito Babaya, Michiko Hamanaka, Masayoshi Kobayashi, Kiyoshi Tsukamoto, Tomoki Yamano, Masataka Ikeda, Naohiro Tomita
A 67-year-old woman was diagnosed with cecal cancer, para-aortic lymph node metastasis, peritoneum dissemination, and left breast cancer. We administered mFOLFOX6 plus panitumumab for cecal cancer and an aromatase inhibitor for her breast cancer. She received 7 courses of systemic chemotherapy and showed a partial response. She additionally received 5 courses of mFOLFOX6 plus panitumumab. We performed ileocecal resection, sigmoidectomy, right oophorectomy, dissection of the para-aortic lymph nodes, and peritoneal dissemination...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29389675/recovery-from-reproductive-impact-of-androgen-abuse
#16
Maria A Christou, Stelios Tigas
PURPOSE OF REVIEW: To summarize recent data on the adverse reproductive consequences of androgen abuse, focusing on the recovery of reproductive function following androgen discontinuation. RECENT FINDINGS: Evidence is mostly based on case reports and observational studies. Androgen abuse leads to a state of hypogonadotropic hypogonadism associated with impaired spermatogenesis, testicular atrophy, gynecomastia as well as menstrual irregularities, virilization and subfertility...
January 31, 2018: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29382531/gonadal-hormone-receptors-underlie-the-resistance-of-female-rats-to-inflammatory-and-cardiovascular-complications-of-endotoxemia
#17
Mohammed A El-Lakany, Mohamed A Fouda, Hanan M El-Gowelli, Sahar M El-Gowilly, Mahmoud M El-Mas
The male gender is more vulnerable to immunological complications of sepsis. Here, we tested the hypotheses that female rats are protected against endotoxemia-evoked hypotension and cardiac autonomic dysfunction, and that gonadal hormone receptors account for such protection. Changes in blood pressure, heart rate, and cardiac sympathovagal balance caused by i.v. lipopolysaccharide (LPS) were determined. In male rats, LPS elevated serum TNFα together with falls in blood pressure and rises in heart rate. The spectral index of cardiac sympathovagal balance (low-frequency/high-frequency ratio, LF/HF) was reduced by LPS, suggesting an enhanced parasympathetic dominance...
January 27, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29382051/coumarin-a-natural-privileged-and-versatile-scaffold-for-bioactive-compounds
#18
REVIEW
Angela Stefanachi, Francesco Leonetti, Leonardo Pisani, Marco Catto, Angelo Carotti
Many naturally occurring substances, traditionally used in popular medicines around the world, contain the coumarin moiety. Coumarin represents a privileged scaffold for medicinal chemists, because of its peculiar physicochemical features, and the versatile and easy synthetic transformation into a large variety of functionalized coumarins. As a consequence, a huge number of coumarin derivatives have been designed, synthesized, and tested to address many pharmacological targets in a selective way, e.g., selective enzyme inhibitors, and more recently, a number of selected targets (multitarget ligands) involved in multifactorial diseases, such as Alzheimer's and Parkinson's diseases...
January 27, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29380951/effects-of-short-term-sex-steroid-suppression-on-dietary-fat-storage-patterns-in-healthy-males
#19
Corey A Rynders, Stacy L Schmidt, Audrey Bergouignan, Tracy J Horton, Daniel H Bessesen
Hypogonadism in males is associated with increased body fat and altered postprandial metabolism, but mechanisms remain poorly understood. Using a cross-over study design, we investigated the effects of short-term sex hormone suppression with or without testosterone add-back on postprandial metabolism and the fate of dietary fat. Eleven healthy males (age: 29 ± 4.5 year; BMI: 26.3 ± 2.1 kg/m2 ) completed two 7-day study phases during which hormone levels were altered pharmacologically to produce a low sex hormone condition (gonadotropin releasing hormone antagonist, aromatase inhibitor, and placebo gel) or a testosterone add-back condition (testosterone gel)...
January 2018: Physiological Reports
https://www.readbyqxmd.com/read/29380528/efficacy-of-management-strategies-for-aromatase-inhibitor-induced-arthralgia-in-breast-cancer-patients-a-systematic-review
#20
REVIEW
Nicole Nahm, Susie Mee, Gavin Marx
Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect. Eligible studies were retrieved from computer searches of Medline, Cochrane and Embase and the significant intervention groups were identified. The risk of bias of selected studies was evaluated and the relevant data items were extracted, summarized and analyzed...
January 30, 2018: Asia-Pacific Journal of Clinical Oncology
keyword
keyword
4026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"